Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Black Diamond Therapeutics Inc
BDTXCurrent price
5.4 USD
-0.1 USD (-1.82%)
Last closed
5.58 USD
Company
www.blackdiamondtherapeutics.com
ISIN
US09203E1055
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
344 679 872 USD
Yield for 12 month
+53.85 %
1Y
3Y
5Y
10Y
15Y
BDTX
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Address: One Main Street, Cambridge, MA, United States, 02142
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
13.83 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-437 000 USD
Last Year
-3 238 000 USD
Current Quarter
-86 000 USD
Last Quarter
-86 000 USD
Key Figures BDTX
1 year
3 years
5 years
10 years
EBITDA
-86 870 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-40.41 %
PEG Ratio
–
Return On Equity TTM
-83.38 %
Wall Street Target Price
13.83 USD
Revenue TTM
–
Book Value
1.97 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-1.5 USD
Diluted Eps TTM
-1.5 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics BDTX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BDTX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation BDTX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-1.9169
Price Book MRQ
3.1046
Financials BDTX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators BDTX
For 52 weeks
1.62 USD
7.66 USD
50 Day MA
5.47 USD
Shares Short Prior Month
4 438 217
200 Day MA
4.55 USD
Short Ratio
13.73
Shares Short
6 013 911
Short Percent
17.93 %
BeatStart